The last special issue on Lung cancer covered some well-known driver mutations in lung adenocarcinomas, such as EML4-ALK, ROS1 and RET. In this issue, EGFR and BRAF is included too. Key changes in the management of unresectable NSCLC stage III during the last decades and challenge of active research are reviewed. The state of radiotherapy and the management of elderly patients are also described.
Together with the last issue, the two issues provide practical information epitomizing the rapid progress in the field of lung cancer today and instilling in physicians the confidence derived from this knowledge when dealing with patients. We hope these information would contribute to the surgeons in their clinical practices in treatment of lung cancer.